A Multicenter, Randomized, Parallel Group, Double Blind, Multiple Dose, Placebo Controlled Study to Assess the Efficacy and Safety of MNK-1411 in Male Subjects 4 to 8 Years of Age With Duchenne Muscular Dystrophy
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2018
At a glance
- Drugs Tetracosactide (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Acronyms BRAVE
- Sponsors Mallinckrodt plc
- 02 Aug 2018 According to a Mallinckrodt plc media release, first patient has been enrolled in this study.
- 26 Feb 2018 Planned End Date changed from 1 Apr 2021 to 1 Aug 2020.
- 26 Feb 2018 Planned primary completion date changed from 1 Mar 2021 to 1 Aug 2020.